ClearPoint Neuro Posts 43% Q1 Revenue Growth to $12.1M, Margin Rises to 64%
CLPT•ClearPoint Neuro reported Q1 2026 revenue of $12.1M, reflecting 43% overall growth and 25% organic device growth, while gross margin expanded to 64%. The company expanded its activated installed base to over 175 centers, secured FDA clearance for its Velocity Alpha MR drill, and held $35.6M in cash.
1. Q1 Financial Results
The company reported Q1 revenue of $12.1M, up 43% from $8.5M year-over-year, driven by a 25% increase in organic device sales and 16% total organic growth. Gross margin expanded to 64%, operating expenses rose 44% to $16.2M, and cash and equivalents totaled $35.6M at quarter-end.
2. Operational Milestones
During the quarter, the activated installed base grew to over 175 global centers, and the firm received FDA clearance for its Velocity Alpha MR high-speed surgical drill. It also secured a Medical Device License from Health Canada and completed its first commercial drug delivery procedure in the Asia-Pacific region.
3. Strategy and Outlook
Integration of the IRRAflow portfolio delivered early revenue and cost synergies, while the company maintains collaborations with over 60 biopharma partners for cell and gene therapy trials. Management reaffirmed 2026 revenue guidance of $52M to $56M and anticipates double-digit growth across its four strategic pillars.
